Cervical CancerNCT05539274
Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus
An observational study of Cervical Cancer, run by Hossam Hassan Aly Hassan El Sokkary at 1 site in Egypt.
Trial summary
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Cervical Cancer
- What is being tested?
- human papilloma virus testing and genotyping in cervical cancer cases
- How many people
- 70 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jul 2019to 31 Jul 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- Child, Adult, Older adult
Study population: cervical cancer cases
Who may be able to join
- cervical cancer
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
About this study
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer
- Conditions
- Cervical Cancer
- Being tested
- human papilloma virus testing and genotyping in cervical cancer cases
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
human papilloma virus testing and genotyping in cervical cancer casesDiagnostic test
an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
| Study group | Role | What they receive |
|---|---|---|
| cervical cancer group, control group | Not described Receives: Diagnostic Test: human papilloma virus testing and genotyping in cervical cancer cases |
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of human papilloma virus infections and genotyping using real time PCR
Measured: 10 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2022
- Study start1 Jul 2019
- Primary completion1 Jun 2022
- Study completion31 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hossam Hassan Aly Hassan El Sokkary
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Hossam Hassan Aly Hassan El Sokkary, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05539274
- Sponsor's protocol ID
- Sokkary11
- Status last verified
- Sep 2022
- First submitted
- 8 Sep 2022
- Last updated
- 3 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus
- ClinicalTrials.gov ID
- NCT05539274
- Acronym / sponsor ID
- Sokkary11
- Conditions
- Cervical Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Hossam Hassan Aly Hassan El SokkaryUniversity, hospital or other
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 1 Jun 2022 (actual)
- Study completion
- 31 Jul 2022 (actual)
- First posted
- 14 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| cervical cancer group, control group | – | Diagnostic Test: human papilloma virus testing and genotyping in cervical cancer cases |
Who may qualify
- Sex
- Female only
- Age groups
- Child, Adult, Older adult
- Study population
- cervical cancer cases
Key inclusion criteria (1 listed)
- cervical cancer
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| human papilloma virus testing and genotyping in cervical cancer casesan observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush. | Diagnostic test | cervical cancer group, control group |
Primary outcome
Detection of human papilloma virus infections and genotyping using real time PCR
Time frame: 10 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2022.
- Individual participant dataSharing planned: No
Related trials for Cervical Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cervical Cancer, run by Hossam Hassan Aly Hassan El Sokkary at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of human papilloma virus infections and genotyping using real time PCR (time frame: 10 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2022.